<?xml version="1.0" encoding="UTF-8"?>
<p>RSV infection can be treated with ribavirin, which is the only licensed drug for the treatment of this virus. However, ribavirin is difficult to use, costly, and teratogenic, and there is weak evidence for its efficacy. Ribavirin is typically used in severe cases that occur in immunocompromised subjects (Brendish and Clark, 
 <xref rid="B10" ref-type="bibr">2017</xref>). Although several new drugs against RSV are in development, and it is likely that in next few years some of them will be licensed for universal use, the present treatment of RSV infection remains based on supporting measures, such as hydration and O
 <sub>2</sub> administration (Xing and Proesmans, 
 <xref rid="B85" ref-type="bibr">2019</xref>).
</p>
